The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced the renewal of a two-year relationship with HealthCarePoint, creators of the BlueCloud® (nominated as one of the top business and technology innovations of 2015). HealthCarePoint’s mission is to do everything possible to improve the healthcare and clinical research systems by increasing transparency and becoming more accountable to patients, subjects and the public in general. HealthCarePoint will participate as a Global Impact Partner (GIP) and align with 30 other sponsors, CROs, and service providers dedicated to promoting high-level communication and meaningful collaboration between industry stakeholders and clinical research sites globally.
“When Global Impact Partners renew their partnership with us, it’s because they are as committed to the sites as we are. It speaks volumes about SCRS as we continue our work in tandem with partners like HealthCarePoint who also want our profession to be the best that it can be. We are excited to continue working with them,” said Christine Pierre, president of SCRS.
“Part of our mission is to support organizations that have a passion, drive and motivation to make a difference in our industry,” said Al O. Pacino, President of HealthCarePoint. “From the beginning, we have had a strong supporting relationship with SCRS. Our missions underline the mutual support for the continued effort of long term site sustainability. We are happy to continue to work in tandem partnership for the benefit of investigator sites worldwide.”
As a Global Impact Partner (GIP), HealthCarePoint will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS.
###
About SCRS
SCRS is a global trade organization founded in 2012 which represents over 2,600 research sites in 42 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org.
About HealthCarePointâ¨HealthCarePoint’s BlueCloud® e-applications are used in 162 countries by over 750,000 healthcare professionals, 42 Sponsors, 14 CROs, 8 IRBs, dozens of universities and thousands of healthcare organizations. BlueCloud® e-applications work together as one system, empowering industry stakeholders to organize, centralize, connect, share and deliver information, credentials, education, training, standards and other activities, between organizations in “real-time” saving our industry millions of dollars in duplication, wasted time and unnecessary redundancies. After a 13-year incubation period, BlueCloud® is no longer and unproven concept, but a true reality that is saving industry stakeholders’ time, money and ultimately saving lives. Visit HealthCarePoint.com.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.